Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy (2020)
Sequence: CRGDKGPDC
| Experiment Id | EXP002289 |
|---|---|
| Paper | Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy |
| Peptide | iRGD |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | 355 ng iRGD per mg SPNP |
| Rna Concentration | ~25 pmol siRNA per mg SPNP |
| Mixing Ratio | encapsulated during EHD jetting |
| Formulation Format | synthetic protein nanoparticle (SPNP) |
| Formulation Components | polymerized HSA + OEG + PEI + iRGD + STAT3 siRNA |
| Size Nm | 220.00 |
| Zeta Mv | |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | GL26 murine glioma cells |
| Animal Model | |
| Administration Route | cell incubation |
| Output Type | gene knockdown |
| Output Value | ↓ STAT3 protein expression |
| Output Units | |
| Output Notes | Western blot; reduced lysosomal colocalization; enhanced cytosolic delivery |
| Toxicity Notes | no cytotoxicity observed |
| Curation Notes |